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The healing response after implantation of a
prosthetic vascular graft is characterized by accumu-
lation of smooth muscle cells (SMCs) beneath an
advancing layer of endothelium.1 The accumulation
of SMCs occurs by the processes of migration and
proliferation. The factors mediating these processes
remain poorly understood, but potential regulators
include platelet-derived growth factor (PDGF) as
well as other growth factors, cytokines, and extracel-
lular matrix molecules. The role of PDGF has gen-
erated considerable interest because PDGF is a
potent SMC mitogen and chemotactic factor, and
PDGF production is elevated in graft segments,
compared with native aorta.2-6 Early after implanta-
tion, the high levels of PDGF may reflect release
from platelets and leukocytes deposited onto the
graft surface, but PDGF production remains elevat-
ed in grafts for at least 2 years after implantation.5
Cells of the neointima, specifically the SMCs, are
responsible for much of the chronically increased
PDGF production.7
Enhanced SMC migration is an important mech-
anism by which PDGF mediates vascular lesion for-
mation. The role of PDGF in controlling SMC
migration from the media into the neointima is
demonstrated in studies of arterial injuries. Ferns et
al8 show that infusion of antibody to PDGF after
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Objective: Previous studies on smooth muscle cells (SMCs) harvested from implanted
synthetic grafts demonstrate increased production of platelet-derived growth factor
(PDGF) but decreased proliferative response compared with aortic SMCs. The purpose
of this study was to determine the migratory response of graft versus aortic SMCs.
Methods: Thoracoabdominal grafts were implanted in beagles. The SMCs were harvested
from the graft and infrarenal aorta. Migration was determined with the use of a razor-
scrape assay and computerized image analysis.
Results: The mean distance migrated and the number of cells that migrated were greater
in graft SMCs at baseline (185 ± 18 µm and 108 ± 17 cells) compared with aortic cells
(110 ± 10 µm and 42 ± 5 cells)(P < .05). Baseline differences persisted after treatment
with antibodies to PDGF. The addition of PDGF (10 ng/mL) resulted in increased
migration in both graft (229 ± 23 µm and 146 ± 20 cells) and aortic SMCs (130 ± 9
µm and 70 ± 5 cells) compared with baseline (P < .05). The relative increase in response
to PDGF was similar between the two groups (P = not significant).
Conclusions: Graft SMCs differ phenotypically from aortic SMCs; they exhibit increased
basal migration that is independent of autocrine stimulation by PDGF. In contrast to
their blunted proliferative response, graft SMCs have a similar migratory response to
PDGF compared with aortic SMCs. (J Vasc Surg 2000;31:953-9.)
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balloon catheter injury of rat carotid arteries does
not alter proliferation but decreases neointima for-
mation by reducing SMC migration across the inter-
nal elastic lamina. Jawien et al9 demonstrated that
infusion of PDGF-BB increases the intimal lesion
after arterial injury by stimulating medial SMC
migration to the neointima. These studies support
the importance of PDGF in promoting SMC migra-
tion into areas of injury.
For growth factors such as PDGF to affect graft
healing and stimulate ongoing proliferation and
migration of SMCs along the graft, SMCs must be
capable of responding to these agents. Our earlier
studies demonstrate that graft SMCs produce
PDGF, but that their proliferative response to
PDGF is blunted, compared with aortic SMCs.10
The blunted proliferative response of graft SMCs
seems to be related to downregulation of PDGF
receptors. Others have shown that in SMCs the sig-
naling pathway for migration differs from that for
proliferation.11,12 The current investigation explores
the migratory response of graft SMCs to PDGF.
MATERIALS AND METHODS
Graft implantation and removal. Cooley
Double-Velour knitted Dacron grafts with internal
diameters of 6 mm (Meadox Medicals, Inc,
Oakland, NJ) and lengths of 20 to 22 cm were
implanted in the thoracoabdominal position in adult
female beagles as previously described.7 The proto-
col for the animal studies was approved by the
Institutional Review Board. Care complied with the
Guide for the Care and Use of Laboratory Animals
(Institute of Laboratory Animal Resources,
Commission on Life Sciences, National Research
Council. Washington: National Academy Press;
1996).
At the time of graft removal, grafts and native
vessels were carefully isolated, flushed with tissue
culture medium (M199; Sigma Chemical Co; St
Louis, Mo), and excised. Fibrous tissue on the graft
exterior was carefully removed. The graft and aorta
were opened and divided, which yielded graft and
aortic segments. The entire graft, except the 2 cm
adjacent to the anastomosis, was used for cell har-
vest. Aorta from 1 cm distal to the anastomosis to
the aortic trifurcation was pinned on Sylgard 184
elastomer discs (Dow Corning, Corp, Midland,
Mich) and readied for cell harvest in M199.
Cell harvest and culture conditions.
Endothelial cells were removed from the segments
with a rounded spatula after incubation in M199 con-
taining 630 U/mL collagenase A (Boehringer
Mannheim Biochemicals, Indianapolis, Ind) for 10
minutes at 37°C in a 5% carbon dioxide atmosphere.
The medial layer of the aorta was then mechanically
harvested, and the media and graft were divided into
2 × 2-mm2 pieces. These pieces were incubated for 2
hours in M199 that contained 15 U/mL elastase type
III (Sigma), 170 U/mL collagenase A, 2 mg/mL
crystalline bovine serum albumin (Boehringer
Mannheim), and 0.375 mg/mL soybean trypsin
inhibitor (Boehringer Mannheim). The SMCs were
then collected by centrifugation at 300g for 5 minutes
and resuspended in M199. The identity and homo-
geneity of the SMC population were confirmed
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Fig 1. Migration assay for graft and aortic SMCs. Subconfluent cells were scraped with a razor, then
allowed to migrate onto the denuded area. After 24 hours, the cells were fixed and stained. With the
use of computerized image analysis, migration was assessed in terms of both distance and number of
cells migrating. Representative images of graft and aortic SMCs are shown.
immunohistochemically by antibody to SMC α-actin
(Sigma). The SMCs were plated in serum-coated tis-
sue wells and grown in M199 with 20% fetal bovine
serum (FBS) (Hyclone Laboratories, Logan, Utah).
The SMCs were grown to confluence, then passaged
by trypsinization and subculturing.
SMC migration assay. Second passage cells
were plated in twelve-well plates at 50,000 cells per
cm2 and grown to subconfluence in M199 with 20%
FBS to assess SMC migration. The cells were then
made quiescent in M199 with 0.5% FBS for 48
hours. A razor blade was used to create a denuded
area on the plates as previously described.13 The
plates were rinsed twice to remove all scraped cells.
The cells were then placed in DME/F12 (Irvine
Scientific, Santa Ana, Calif) with 0.5% FBS and
allowed to migrate onto the denuded area for 24
hours. After 24 hours, the cells were fixed in
methanol and stained with Mayer’s modified hema-
toxylin (PolyScientific, Bay Shore, NY).
Digital microscopic images of the plates were
then analyzed on a personal computer using Image
software of the National Institutes of Health
(Bethesda, Md). Migration was assessed in terms of
both distance and number of cells migrating onto
the denuded area. Distance was expressed in terms
of the mean distance that the cells migrated onto the
denuded area. The migrating cell number was nor-
malized to a cell count performed on a full visual
field of the unscraped portion of the plates to negate
any differences in cell density on the plates. All assays
were performed in triplicate.
The absence of SMC proliferation as a con-
founding factor in this migration assay was con-
firmed by control assays performed with the addi-
tion of the antiproliferative agents mitomycin C
(Sigma) and hydroxyurea (Sigma). The incubation
of SMCs in 10 mmol/L of mitomycin C for 2 hours
before the razor injury or in 1 mmol/L of hydrox-
yurea for 24 hours after the injury did not change
the results of the assay. The effectiveness of these
agents, with regard to inhibiting proliferation, was
confirmed by the addition of [3H] thymidine fol-
lowed by autoradiography.
Reagents. The PDGF-AB was purchased from
Upstate Biotechnologies, Inc (Lake Placid, NY).
Anti–PDGF-AB was purchased from Promega
(Madison, Wis).
Statistical analysis. Data were expressed as
mean ± SE of the mean and compared by Student
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Fig 2. Unstimulated migration of graft and aortic SMCs. Under basal conditions, graft SMCs demon-
strated increased distance and number of cells migrated compared with aortic SMCs (*P < .05; Student
paired t test)(n = 8).
Fig 3. Dose response curves for PDGF. Migratory
response to PDGF was determined for both graft and aor-
tic SMCs using concentrations of 0, 0.1, 1, 10 and 25
ng/mL. In general, 10 ng/mL achieved maximal or near-
maximal response. A typical curve is depicted.
paired t test. Statistical significance was assumed if P
was less than .05.
RESULTS
Baseline migration. Studies were performed in
control media on graft and aortic SMCs from each
of the eight dogs with Dacron grafts implanted for
an average of 20 weeks (range, 16-29 weeks) to
determine differences in baseline migration. Both in
terms of mean distance migrated and number of cells
migrated, graft SMCs exhibited increased baseline
migration compared with aortic SMCs (Figs 1 and
2). The mean distance migrated by graft SMCs aver-
aged 185 ± 18 µm compared with 110 ± 10 µm by
aortic SMCs (P = .0001; Student paired t test.) The
number of graft SMCs migrating averaged 108 ± 17
cells compared with 42 ± 5 aortic SMCs (P = .006;
Student paired t test).
Response to PDGF. Parallel studies were per-
formed on the cells harvested from all eight dogs
with the addition of PDGF-AB at a concentration of
10 ng/mL to determine the effect of PDGF on
SMC migration. Dose response curves showed that
this concentration achieved maximal or near maxi-
mal response for graft and aortic SMCs (Fig 3).
Graft SMCs demonstrated a significant increase in
both mean distance migrated (229 ± 23 µm) and
number of cells migrating (146 ± 20 cells) when
exposed to PDGF (Fig 4). The relative increase in
these parameters did not differ significantly from
that seen in aortic SMCs.
Blocking studies. Assays were run in parallel on
the cells from two of the dogs with antibodies to
PDGF to determine if differences in baseline migra-
tion resulted from the known increased production
of PDGF by graft SMCs. Migration in the presence
of 25 µg of anti–PDGF-AB was compared with
baseline control. Addition of this antibody had little
effect on migration of either graft or aortic SMCs
and did not negate the increased basal migration of
the graft SMCs (Fig 5).
DISCUSSION
The migration of SMCs from the adjacent artery
onto a graft occurs early after graft implantation and
is an important source of cells inhabiting the graft.
Clowes et al1 demonstrated that SMCs migrate with
endothelial cells from the adjacent artery and prolif-
erate on the graft to produce a neointima. Previous
studies have shown that the SMCs of this neointima
are functionally different than those of normal arter-
ies. These SMCs have higher basal rates of prolifera-
tion, produce certain growth factors (particularly
PDGF), and have a lower proliferative response to
exogenous growth factors than normal arterial
SMCs.7,10 This study shows that graft SMCs also
have higher unstimulated migration rates compared
with normal arterial SMCs.
These differences are not unique to graft SMCs.
Others have described similar functional changes in
SMCs harvested from injured arteries in experimen-
tal animals, spontaneously hypertensive rats, and
restenotic atherosclerotic lesions.14-20 In all these
cases, the SMCs appear to have increased expression
of an “immature” phenotype. Besides the functional
differences, many of these cells have also been
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Fig 4. Migratory response to PDGF. Both graft and aortic SMCs demonstrated increased distance and
number of cells migrated when exposed to PDGF (10 ng/mL) compared with control (*P < .05;
Student paired t test). The relative increase was similar between the two groups (P = not signifcant;
Student paired t test)(n = 8).
shown to display the embryonic myosin heavy chain
isoform specific for dedifferentiated SMCs. In fact,
Zhang et al21 have recently shown that SMCs in vein
grafts display the embryonic myosin heavy chain iso-
form specific for immature, dedifferentiated SMCs.
The expression of the immature phenotype seems to
be relatively stable since our studies were performed
on grafts implanted for 20 weeks. Zhang et al21
noted that the phenotype of many neointimal SMCs
in vein grafts in rabbits gradually returned to the dif-
ferentiated phenotype, but that a small number of
SMCs retained the immature phenotype even at 6
months after graft implantation.
The factors responsible for these phenotypic
changes are not certain. The reexpression of a fetal
phenotype may be a response to arterial injury.
Clearly, the immature SMCs seem to be activated in
processes such as intimal hyperplasia.22 Alternatively,
they may simply represent a subpopulation of arter-
ial wall SMCs responding to the “injury” of graft
implantation. The heterogeneity of SMCs in the
normal arterial wall is well recognized. The coexis-
tence of differentiated and “immature” SMC phe-
notypes is demonstrated in normal adult canine and
human arteries using response to mitogens or
myosin isoforms to delineate SMC differentia-
tion.23,24 The implantation of the graft may result in
a selection process, where the graft becomes colo-
nized by the aortic SMCs that possess the highest
migratory capacity.
Although graft SMCs possess an altered pheno-
type, another possible alternate explanation for the
increased migration of graft SMCs is the production
of high levels of cytokines, particularly PDGF, which
result in autocrine stimulation. We have shown that
graft SMCs secrete more PDGF than aortic SMCs,7
which could be responsible for the increased chemo-
kinetic activity of these cells. Our results, however,
show that differences in migration persist after the
addition of blocking antibodies to PDGF, suggest-
ing that differences in migration are due to a phe-
notypic change in the graft SMC rather than
autocrine stimulation by PDGF. The results do not
preclude the possibility that other cytokines may be
responsible for the increased basal migration.
Graft SMCs respond to PDGF with increased
migration that is equivalent to aortic SMCs. This
finding is in contrast to previous studies showing
that the proliferative response of graft SMCs to
PDGF is severely blunted compared with aortic
SMCs. The reason for this dichotomy is unclear.
One possible explanation is greater sensitivity to
PDGF stimulation of migration compared with pro-
liferation. This is possible because the signaling
pathway for PDGF-mediated proliferation and
migration differs.25-27 In fact, Abedi et al28 have
shown in rat aortic SMCs that the concentration of
PDGF required for half-maximal migration is signif-
icantly lower than that for half-maximal prolifera-
tion. However, the concentration of PDGF used in
our studies is sufficient to stimulate near-maximal
proliferative and migratory responses.
Another possible explanation for the variation in
proliferative and migratory response is the difference
in the isoform of PDGF receptor expressed by the
two types of cells. Ligand binding to the PDGF alpha
receptor results in increased proliferation but
decreased migration in baboon SMCs, whereas lig-
and binding to the PDGF beta receptor increases
both proliferation and migration.29,30 It is possible
then that differences in the number or the propor-
tion of the isoform expressed could explain the dif-
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Fig 5. Blocking studies. Addition of antibodies to PDGF had little effect and did not negate the increased baseline migra-
tion of graft SMCs compared with aortic SMCs (n = 2).
ferences between graft and aortic SMCs with respect
to proliferative and migratory response to PDGF. We
have previously shown that graft SMCs have
decreased binding of exogenous radiolabeled PDGF,
suggesting downregulation of the PDGF receptors in
these cells or occupation of the receptors by the
endogenously produced PDGF.10 Additional studies
in our laboratory suggest that both canine aortic and
graft SMCs express very few alpha receptors. Thus, it
appears unlikely that the variation in proliferative and
migratory responses results solely from alterations in
the type or number of PDGF receptors.
The most likely explanation for the differences in
aortic and graft SMC response is that it is a result of
the phenotypic changes themselves. Majack et al12
have shown that rat SMCs isolated from the neointi-
ma after balloon injury exhibit a severely diminished
proliferative response, despite the presence of numer-
ous functional PDGF receptors in these cells. They
retain normal migratory response to PDGF and sev-
eral other cytokines. The authors postulate that the
signaling pathway for proliferation is blocked, where-
as the signaling pathway to migration remains intact
in the immature cell type. The data from our labora-
tory suggest that graft SMCs are similarly altered in
their proliferative and migratory response to PDGF,
reinforcing the similarity in characteristics in the
neointimal SMCs after arterial injury and graft
implantation. Further studies on these signaling
pathways may help elucidate the exact phenotypic
changes occurring within these altered cells.
In summary, we have shown that in a canine
model, SMCs harvested from prosthetic grafts exhib-
it increased basal migration compared with aortic
SMCs. The increase in migration cannot be explained
by autocrine stimulation from endogenously pro-
duced PDGF as evidenced by the failure of antibody
to PDGF to reduce migration rates to that of aortic
SMCs. Furthermore, despite a previously demonstrat-
ed diminished proliferative response to PDGF, the
graft SMCs exhibit a similar migratory response to
PDGF when compared with aortic SMCs. The results
suggest that phenotypic changes in graft SMCs lead
to altered basal characteristics and modulate their
response to various stimuli. An improved understand-
ing of these phenotypic changes is necessary if we are
to develop successful strategies to treat abnormal
graft-healing responses, such as anastomotic intimal
hyperplasia.
We thank Meadox Medicals, Inc, for donating the
grafts.
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